Literature DB >> 3129560

Studies on the effect of methotrexate on macrophage function.

S K Hu1, Y L Mitcho, A L Oronsky, S S Kerwar.   

Abstract

Time course studies in rat adjuvant arthritis have shown that resident peritoneal macrophages synthesize large amounts of interleukin-1 (IL-1) on Day 10-11 postadjuvant immunization. Expression of Ia antigen on these macrophages increased rapidly between Day 15 to Day 20 postadjuvant treatment and remained at these high levels on Day 25. If these adjuvant immunized rats were treated with low doses of methotrexate, resident peritoneal macrophages appeared to synthesize lower amounts of IL-1 and their Ia expression was decreased. Methotrexate, in vitro, has no effect on lipopolysaccharide induced IL-1 synthesis by resident peritoneal macrophages.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129560

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 2.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 3.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 4.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 5.  Corticosteroid sparing agents in asthma.

Authors:  J M Hill; A E Tattersfield
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

6.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression.

Authors:  M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 7.  New approaches to the treatment of rheumatoid arthritis.

Authors:  P A Miescher; Y P Huang; R H Zubler
Journal:  Springer Semin Immunopathol       Date:  1988

8.  Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis.

Authors:  Thommey P Thomas; Sascha N Goonewardena; Istvan J Majoros; Alina Kotlyar; Zhengyi Cao; Pascale R Leroueil; James R Baker
Journal:  Arthritis Rheum       Date:  2011-09

9.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

10.  Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model.

Authors:  Y Huang; K Salu; X Liu; S Li; L Wang; E Verbeken; J Bosmans; I De Scheerder
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.